Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CVAC | US
0.02
0.67%
Healthcare
Biotechnology
30/06/2024
04/10/2024
3.02
2.96
3.07
2.96
CureVac N.V. a clinical-stage biopharmaceutical company focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines such as mRNA-based vaccine candidates CV2CoV which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 a prophylactic mRNA-based vaccine which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV which is in Phase 1 clinical trial against influenza as well as vaccine for lassa fever yellow fever respiratory syncytial virus rotavirus malaria and universal influenza. The company also develops RNA-based cancer therapies including CV8102 which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma as well as squamous cell cancer of skin head and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen Germany.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
37.8%1 month
65.9%3 months
60.5%6 months
76.9%-
5.24
1.61
0.10
0.07
-0.66
6.60
-
-270.34M
679.69M
679.69M
-
-493.58
-
90.50
-54.30
11.11
13.76
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.44
Range1M
0.74
Range3M
1.18
Rel. volume
0.70
Price X volume
1.04M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Opthea Limited | OPT | Biotechnology | 4.48 | 746.87M | -2.61% | n/a | -264.65% |
AbCellera Biologics Inc | ABCL | Biotechnology | 2.5 | 736.66M | 0.81% | n/a | 6.49% |
Arbutus Biopharma Corporation | ABUS | Biotechnology | 3.84 | 724.92M | -1.54% | n/a | 6.09% |
Erasca Inc. Common Stock | ERAS | Biotechnology | 2.54 | 717.56M | 0.79% | n/a | 11.96% |
Pliant Therapeutics Inc. | PLRX | Biotechnology | 11.53 | 701.04M | 5.68% | n/a | 15.34% |
Terns Pharmaceuticals Inc. | TERN | Biotechnology | 8.27 | 698.29M | 0.85% | n/a | 0.11% |
Mineralys Therapeutics Inc. | MLYS | Biotechnology | 13.88 | 690.21M | 8.44% | n/a | 0.00% |
Avid Bioservices Inc | CDMO | Biotechnology | 10.63 | 678.14M | -1.02% | n/a | 353.77% |
ORIC Pharmaceuticals Inc | ORIC | Biotechnology | 9.61 | 677.91M | -1.84% | n/a | 0.92% |
Mereo BioPharma Group plc | MREO | Biotechnology | 4.4 | 676.95M | 2.56% | n/a | 7.83% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.66 | 0.76 | Cheaper |
Ent. to Revenue | 6.60 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 1.61 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 60.52 | 74.67 | Par |
Debt to Equity | 0.10 | -1.82 | Expensive |
Debt to Assets | 0.07 | 0.26 | Cheaper |
Market Cap | 679.69M | 3.73B | Emerging |